TFF Group (TFFP)
Dec 13, 2024 - TFFP was delisted (reason: winding down operations)
0.0650
-0.0977 (-60.05%)
Inactive · Last trade price on Dec 12, 2024
TFF Pharmaceuticals Revenue
In the fiscal year ending April 30, 2025, TFF Pharmaceuticals had annual revenue of 425.43M EUR, down -12.56%. TFF Pharmaceuticals had revenue of 185.22M in the half year ending April 30, 2025, a decrease of -10.60%.
Revenue (ttm)
425.43M EUR
Revenue Growth
-12.56%
P/S Ratio
0.99
Revenue / Employee
270,114 EUR
Employees
1,575
Market Cap
479.94M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2025 | 425.43M | -61.12M | -12.56% |
Apr 30, 2024 | 486.55M | 46.77M | 10.63% |
Apr 30, 2023 | 439.79M | 137.17M | 45.33% |
Apr 30, 2022 | 302.62M | 41.74M | 16.00% |
Apr 30, 2021 | 260.88M | -18.79M | -6.72% |
Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTFFP News
- 8 months ago - TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration - PRNewsWire
- 11 months ago - TFF Pharmaceuticals Announces It Will Wind Down Operations - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing - GlobeNewsWire
- 1 year ago - TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing - GlobeNewsWire